^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors

Excerpt:
...132 patients enrolled in cohorts with doses ranging from 15-50 μg RO7198457 in combination with atezolizumab….patients had low levels of PD-L1 expression (93% patients with <5% PD-L1 expression on tumor cells, 79% patients with <5% expression on immune cells)....RO7198457 in combination with atezolizumab has a manageable safety profile consistent with the mechanisms of action of the study drugs and induces significant levels of neoantigen-specific immune responses.
DOI:
10.1158/1538-7445.AM2020-CT301